AU2020312560A1 - Fusion toxin proteins for treatment of diseases related to CMV infections - Google Patents

Fusion toxin proteins for treatment of diseases related to CMV infections Download PDF

Info

Publication number
AU2020312560A1
AU2020312560A1 AU2020312560A AU2020312560A AU2020312560A1 AU 2020312560 A1 AU2020312560 A1 AU 2020312560A1 AU 2020312560 A AU2020312560 A AU 2020312560A AU 2020312560 A AU2020312560 A AU 2020312560A AU 2020312560 A1 AU2020312560 A1 AU 2020312560A1
Authority
AU
Australia
Prior art keywords
immunotoxin
fold
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020312560A
Other languages
English (en)
Inventor
Thomas Nitschke Kledal
Mette Marie Rosenkilde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Danmarks Tekniske Universitet
Original Assignee
Københavns Universitet
Danmarks Tekniske Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet, Danmarks Tekniske Universitet filed Critical Københavns Universitet
Publication of AU2020312560A1 publication Critical patent/AU2020312560A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020312560A 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to CMV infections Abandoned AU2020312560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186000 2019-07-12
EP19186000.6 2019-07-12
PCT/EP2020/067785 WO2021008840A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to cmv infections

Publications (1)

Publication Number Publication Date
AU2020312560A1 true AU2020312560A1 (en) 2022-03-03

Family

ID=67437717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020312560A Abandoned AU2020312560A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to CMV infections

Country Status (10)

Country Link
US (1) US20220281933A1 (https=)
EP (1) EP3997107A1 (https=)
JP (1) JP2022540877A (https=)
KR (1) KR20220032610A (https=)
CN (1) CN114206944A (https=)
AU (1) AU2020312560A1 (https=)
BR (1) BR112022000417A2 (https=)
CA (1) CA3146798A1 (https=)
MX (1) MX2022000433A (https=)
WO (1) WO2021008840A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4301394A1 (en) * 2021-03-03 2024-01-10 Synklino ApS Compositions for ex vivo organ care

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2038302B1 (en) * 2006-07-03 2012-10-24 INAGEN ApS Immunotoxins for the treatment of diseases related to cmv infection
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP3262063B1 (en) * 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
US10849960B2 (en) * 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

Also Published As

Publication number Publication date
MX2022000433A (es) 2022-04-25
US20220281933A1 (en) 2022-09-08
BR112022000417A2 (pt) 2022-03-03
EP3997107A1 (en) 2022-05-18
CN114206944A (zh) 2022-03-18
CA3146798A1 (en) 2021-01-21
WO2021008840A1 (en) 2021-01-21
JP2022540877A (ja) 2022-09-20
KR20220032610A (ko) 2022-03-15

Similar Documents

Publication Publication Date Title
JP2022001591A (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
CN102281890B (zh) Sparc结合肽及其应用
ES2361621T3 (es) Péptidos de lactoferrina útiles como péptidos de penetración celular.
Falnes et al. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment
CA3086040A1 (en) Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
JP2019151638A (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
CN108137671B (zh) 可溶性pdl-1分子
CA2953827A1 (en) Compositions and methods of use for treating metabolic disorders
JP2018507865A (ja) 肝細胞へのミトコンドリアの標的化移植
US20220281933A1 (en) Fusion toxin proteins for treatment of diseases related to cmv infections
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
KR101778244B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
US20130237476A1 (en) Adipose tissue targeted peptides
US6395875B1 (en) Recombinant soluble adenovirus receptor
CN101914161B (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
JP2001521733A (ja) ヒト上皮増殖因子とヒトアンギオゲニンの融合タンパク質およびその製造方法
JP2022549057A (ja) 分子の細胞内送達のための複合体
WO2015055148A1 (zh) Yap蛋白抑制多肽及其应用
CN114341196B (zh) 融合蛋白及其用途
JP2006527192A (ja) 血管内皮増殖因子融合構築物およびその使用方法
WO2018219301A1 (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN103408654A (zh) 一种rTRAIL突变体-单甲基化聚乙二醇马来酰亚胺偶联物及其应用
US10010625B2 (en) Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin
CN101613410A (zh) 核糖核酸酶与毒蛋白膜转位结构域融合蛋白及其制备方法和用途
CN113842467A (zh) 用于抗体与药物偶联体（adc）制备的中间体及其制备方法和应用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application